RxDoctor Payments Data

Mark Carter, MD

Family Medicine · Hobart, INNPI 1831125806

Payments from drug & device makers

$7,775in general payments, 2019–2025

Across 483 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$657
  • Novo Nordisk$564
  • Pfizer$441
  • Lilly USA, LLC$415
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$403
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,775100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,775 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$66,248
Medicare patients
229
Services billed
1,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$113,052
JanuviaSitagliptin Phosphate75$66,967
JardianceEmpagliflozin75$66,700
TrulicityDulaglutide39$55,237
FarxigaDapagliflozin Propanediol25$26,199
MyrbetriqMirabegron25$23,510
TradjentaLinagliptin18$19,382
JanumetSitagliptin Phos/Metformin Hcl24$18,861
Tresiba Flextouch U-200Insulin Degludec22$16,706
EliquisApixaban12$14,237
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,494
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$9,931
LinzessLinaclotide11$7,019
Breo ElliptaFluticasone/Vilanterol15$6,886
DapagliflozinDapagliflozin Propanediol12$5,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$564$113,052107 claims
Boehringer IngelheimJardiance, Tradjenta$375$86,08293 claims
MerckJanuvia, Janumet$237$85,82999 claims
Lilly USA, LLCTrulicity$415$55,23739 claims
AstraZenecaFarxiga, Symbicort$657$30,40640 claims
Astellas Pharma US IncMyrbetriq$96$23,51025 claims
GSKTrelegy Ellipta, Breo Ellipta$216$20,37934 claims
PfizerEliquis$441$14,23712 claims
AbbVieLinzess, Synthroid$1,510$9,38759 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Hobart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →